Arrive is a biotechnology company founded in 2019 in Silicon Valley, California, with offices in both San Francisco and Singapore. The company is pioneering the use of in-vivo target screening combined with machine learning to tackle age-related diseases. By leveraging cutting-edge AI and advanced biological data, Arrive aims to identify novel therapeutic targets to address the underlying mechanisms of aging, which can contribute to a range of diseases such as cognitive decline, metabolic disorders, and muscle atrophy.

Arrive has established partnerships with major entities, including Roche and the FDA, and is working with these organizations to establish industry standards for AI algorithms in pathology. This collaboration with the FDA is especially significant as the company seeks to integrate AI more widely in healthcare applications​